Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 6
Submit an article Journal homepage
1,344
Views
1
CrossRef citations to date
0
Altmetric
Immunotherapeutics – Short Report

Omalizumab added to allergen immunotherapy increased the effect of therapy in patients with severe local allergic rhinitis

Andrzej Bozeka Clinical Department of Internal Diseases, Dermatology and Allergology in Zabrze, Medical University of Silesia, Katowice, PolandCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2263-2263View further author information
ORCID Icon,
Renata Kozłowskaa Clinical Department of Internal Diseases, Dermatology and Allergology in Zabrze, Medical University of Silesia, Katowice, PolandView further author information
,
Maciej Misiołekb Department of Otorhinolaryngology and Laryngological Oncology in Zabrze, Medical University of Silesia, Katowice, PolandView further author information
,
Wojciech Ścierskib Department of Otorhinolaryngology and Laryngological Oncology in Zabrze, Medical University of Silesia, Katowice, PolandView further author information
&
Radosław Gawlikc Clinical Department of Internal Diseases, Allergology and Clinical Immunology in Zabrze, Medical University of Silesia, Katowice, PolandView further author information
Article: 2097818 | Received 01 Mar 2022, Accepted 01 Jul 2022, Published online: 11 Jul 2022

References

  • Eguiluz-Gracia I, Pérez-Sánchez N, Bogas G, Campo P, Rondón C. How to diagnose and treat local allergic rhinitis: a challenge for clinicians. J Clin Med. 2019;8(7):1. doi: 10.3390/jcm8071062.
  • Rondon C, Blanca – Lopez N, Aranda A, Herrera R, Rodriguez BJ, Canto G, Mayorga C, Torres MJ, Campo P, Blanca M, et al. Local allergic rhinitis: allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen. J Allergy Clin Immunol. 2011;127(4):1069–3. doi: 10.1016/j.jaci.2010.12.013.
  • Rondon C, Campo P, Salas M, Aranda A, Molina A, Gonzales M, Galindo L, Mayorga C, Torres MJ, Blanca M. Efficacy and safety of D. pteronyssinus immunotherapy in local allergic rhinitis: a double-blind placebo-controlled clinical trial. Allergy. 2016;71(7):1057–1061. doi: 10.1111/all.12889.
  • Augé J, Vent J, Agache I, Airaksinen L, Campo Mozo P, Chaker A, Cingi C, Durham S, Fokkens W, Gevaert P, et al. EAACI position paper on the standardization of nasal allergen challenges. Allergy. 2018;73(8):1597–1608. doi: 10.1111/all.13416.
  • Kopp MV, Hamelmann E, Bendiks M, Zielen S, Kamin W, Bergmann KC, Klein C, Wahn U. DUAL study group. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatr Allergy Immunol. 2013;24(5):427–433. doi: 10.1111/pai.12098.
  • Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, Stenglein S, Seyfried S, Wahn U. DUAL study group. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009;39(2):271–279. doi: 10.1111/j.1365-2222.2008.03121.x.
  • Corren J, Diaz-Sanchez D, Saxon A, Deniz Y, Reimann J, Sinclair DS, Davancaze T, Adelman D. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis. Ann Allergy Asthma Immunol. 2004;93(3):243–248. doi: 10.1016/S1081-1206(10)61495-0.
  • Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, Francis JN; Immune Tolerance Network Group. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding. Allergy Clin Immunol. 2007;120(3):688–695. doi: 10.1016/j.jaci.2007.05.034.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.